(E)-3-{3-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]acrylamido}benzoic acid methyl ester | 1373443-05-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-{3-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]acrylamido}benzoic acid methyl ester
• 英文别名: methyl 3-[[(E)-3-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]prop-2-enoyl]amino]benzoate
• CAS: 1373443-05-0
• 化学式: C₂₅H₃₁NO₄
• 分子量: 409.525
• InChiKey: ZEXAUCGQGNXJFD-CCEZHUSRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对特辛基苯酚 在 lithium hydroxide monohydrate 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成 (E)-3-{3-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]acrylamido}benzoic acid methyl ester
  参考文献：
  名称：

  3-（3-（4-（2,4,4-三甲基戊烷-2-基）苯氧基）-丙酰胺基）苯甲酸甲酯作为靶向癌症代谢的新型和双重苹果酸脱氢酶（MDH）1/2抑制剂

  摘要：

  以前，我们报道了使用化学生物学方法，含有（芳氧基乙酰氨基）苯甲酸部分的缺氧诱导因子（HIF）-1抑制剂LW6抑制苹果酸脱氢酶2（MDH2）。对一系列（芳氧基乙酰氨基）苯甲酸的结构-活性关系研究确定了选择性MDH1，MDH2和双重抑制剂，这些抑制剂用于研究MDH酶活性与HIF-1抑制之间的关系。我们假设对MDH1和MDH2的双重抑制可能是靶向癌症代谢的有力方法，并且选择了3-（3-（4-（2,4,4-三甲基戊烷-2-基）苯氧基）丙酰胺基）-苯甲酸甲酯（16c）作为最有效的双重抑制剂。动力学研究表明，化合物16c竞争性抑制MDH1和MDH2。化合物16c抑制线粒体呼吸和缺氧诱导的HIF-1α积累。在使用HCT116细胞的异种移植测定中，化合物16c表现出显着的体内抗肿瘤功效。这一发现提供了具体的证据，即抑制MDH1和MDH2可能为开发针对癌症代谢和肿瘤生长的新型疗法提供有价值的平台。

  DOI：

  10.1021/acs.jmedchem.7b01231

文献信息

• NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：DONGGUK UNIVERSITY GYEONGJU CAMPUS INDUSTRY-ACADEMY COOPERATION FOUNDATION

  公开号：US20200031764A1

  公开（公告）日：2020-01-30

  The present invention relates to a compound exhibiting inhibitory activity of at least one of malate dehydrogenases I (MDH1) and malate dehydrogenases 2 (MDH2), and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The inventors of the present invention have experimentally confirmed that the compound exhibiting the MDH1 and/or MDH2 inhibitory activity has an inhibitory effect on mitochondrial respiration in cancer cells, an excellent inhibitory effect on cancer cell growth, etc. Thus, the compound of the present invention is expected to be effectively used as a pharmaceutical composition for treating cancer.

  本发明涉及一种对苹果酸脱氢酶I（MDH1）和/或苹果酸脱氢酶2（MDH2）至少一种具有抑制活性的化合物，以及包含该化合物作为活性成分的用于预防或治疗癌症的药物组合物。本发明的发明人通过实验证实，表现出MDH1和/或MDH2抑制活性的该化合物对癌细胞线粒体呼吸具有抑制作用，对癌细胞生长具有优异的抑制效果等。因此，本发明的化合物有望被有效地用作治疗癌症的药物组合物。
• ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
  申请人：Lee Kyeong

  公开号：US20130237542A1

  公开（公告）日：2013-09-12

  The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

  本发明涉及一种抑制HF-1活性的化合物，以及该化合物的制备方法和包含该化合物作为活性成分的药物组合物。本发明的化合物通过抑制HIF-1活性而不是通过非选择性细胞毒性表现出抗癌活性，HIF-1是在癌细胞生长和转移中起重要作用的转录因子。因此，根据本发明的化合物或其药用盐抑制HIF-1活性，因此可以用作固体肿瘤如结肠癌、肝癌、胃癌和乳腺癌的治疗剂。此外，根据本发明的化合物或其药用盐还可以用作糖尿病视网膜病变或关节炎的治疗剂的活性成分，当HIF-1诱导的VEGF表达增加时，这些疾病可能会恶化。
• 페녹시아크릴 유도체 및 이의 용도
  申请人：Dongguk University Industry-Academic Cooperation Foundation 동국대학교 산학협력단(220060081783) BRN ▼201-82-04468

  公开号：KR20150088205A

  公开（公告）日：2015-07-31

  본 발명은 페녹시아세틸 유도체 화합물 및 이를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 화합물은 SREBP-1c의 활성 억제 및 FAS 발현 억제능이 우수한바, 비알콜성 지방간 질환을 예방, 개선 또는 치료하기 위한 약학적 조성물 또는 기능성 식품 조성물의 활성성분으로 유용하게 사용될 수 있을 것으로 기대된다.

  这项发明涉及苯氧基乙酰诱导体化合物及其作为有效成分包含在非酒精性脂肪肝预防或治疗药物组合物中的药学组合物。根据本发明，由化合物具有出色的SREBP-1c活性抑制和FAS表达抑制能力，可以预期将其作为预防、改善或治疗非酒精性脂肪肝的药学组合物或功能性食品组合物的活性成分得到有益利用。
• Synthesis and Structure–Activity Relationship of (<i>E</i>)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors
  作者：Ravi Naik、Misun Won、Bo-Kyung Kim、Yan Xia、Hyun Kyung Choi、Guanghai Jin、Youngjin Jung、Hwan Mook Kim、Kyeong Lee

  DOI：10.1021/jm301419d

  日期：2012.12.13

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.
• US8940936B2
  申请人：——

  公开号：US8940936B2

  公开（公告）日：2015-01-27